Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer

BJU International

Volumn 114, Issue 1, 2014, Pages 125-130

  Balbontin, Felipe G ^a   Moreno, Sergio A ^a   Bley, Enrique ^b   Chacon, Rodrigo ^b   Silva, Andres ^b   Morgentaler, Abraham ^c  

^a CLÍNICA SANTA MARÍA   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

brachytherapy; hypogonadism; prostate cancer; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ERECTILE DYSFUNCTION; FATIGUE; GLEASON SCORE; HUMAN; LIBIDO DISORDER; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; ANDROGENS; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84903318834     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12668     Document Type: Article

References (21)

1. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A,. A new era of testosterone and prostate cancer. From physiology to clinical implications. Eur Urol 2014; 65: 115-123
2. Sarosdy MF,. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-541
3. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M,. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 2013; 25: 24-28
4. Caloglu M, Ciezki J,. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology 2009; 74: 1183-1190
5. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672
6. Roddam AW, Allen NE, Appleby P, Key TJ, Endogenous Hormones Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183
7. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaría R, Freedland SJ,. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 2012; 62: 757-764
8. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297
9. Huggins C, Stevens RE Jr, Hodges CV,. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-223
10. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; 190: 639-644
11. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M,. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 1256-1260
12. Agarwal PK, Oefelein MG,. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-536
13. Kaufman JM, Graydon RJ,. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920-922
14. Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-1170
15. Morales A, Black AM, Emerson LE,. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 2009; 103: 62-64
16. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A,. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28: 17-22
17. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W,. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 839-850
18. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998; 83: 989-1001
19. Bianco FJ Jr, Scardino PT, Eastham JA,. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology 2005; 66 (Suppl).): 83-94
20. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528-534
21. Morales A, Schulman CC, Tostain J, Wu FC,. Testosterone deficiency syndrome (TDS) needs to be named appropriately-the importance of accurate terminology. Eur Urol 2006; 50: 407-409